ARTICLE SUMMARY:
Device firms hatch plans to support a restart of more routine healthcare, BIO taps a noted medtech expert for its top spot, regulatory activity in the EU, and more from Brazil, China, Medicare, and FDA.
Restarting elective procedures and routine health screenings are a top focus for many in the medtech sector. Key industry and healthcare groups are out with plans over the past week to help that happen, leading off this latest Pathways’ Picks medtech policy roundup.
